Carl Zeiss Says Restructuring Could Affect up to 1,000 Jobs

Why It Matters

The cuts signal mounting pressure on the ophthalmic device market and could reshape competitive dynamics, while the earnings target shows Zeiss’s urgency to restore profitability amid a sluggish investment environment.

Key Takeaways

• Up to 1,000 global jobs may be eliminated by 2029.
• First‑half revenue fell 5.7% to €991 million ($1.09 bn).
• Adjusted EBITDA dropped to €60.5 million ($66 million) from €112.6 million.
• Zeiss targets > €200 million ($220 million) earnings boost by FY 2028‑29.

Pulse Analysis

Carl Zeiss Meditec, the German specialist in ophthalmic and microsurgery equipment, reported a disappointing first half of fiscal 2025‑26. Revenue slipped 5.7% to €991 million (about $1.09 billion) and adjusted EBITDA fell to €60.5 million ($66 million), driven largely by a slowdown in its intraocular lens segment. The company cited a weakening investment climate across the Americas and heightened geopolitical and regulatory uncertainty as key headwinds. These pressures have forced Zeiss to reassess its growth assumptions and look for ways to shore up profitability.

In response, Zeiss unveiled a three‑year restructuring plan that could eliminate up to 1,000 positions worldwide. The cost‑saving package focuses on streamlining the supply chain, discontinuing low‑margin products, and relocating research and development activities to lower‑cost locations. Administrative expenses will be trimmed through both personnel reductions and non‑material cuts. The initiative dovetails with a broader manufacturing strategy that emphasizes expanding capacity in China while building cost‑efficient sites elsewhere. Together, these moves are designed to generate more than €200 million ($220 million) in annual earnings improvement by FY 2028‑29.

The restructuring underscores a broader shift in the medical‑technology sector, where firms are balancing innovation with tighter cost discipline. For investors, Zeiss’s aggressive target signals confidence that the market will rebound once the Americas’ investment environment stabilizes. Competitors in the intraocular lens space may see an opportunity to capture market share as Zeiss reallocates resources. However, the scale of the job cuts also raises concerns about talent retention and the speed of R&D migration. If executed well, the plan could restore Zeiss’s profit trajectory while reshaping the competitive landscape.